Citations

Clear

6273 citation(s) found for "To, Andrew".

Epidemiology of general anesthesia prior to age 3 in a population‐based birth cohort
Shi, Yu , Hu, Danqing , Rodgers, Erin L., Katusic, Slavica K., Gleich, Stephen J. , Hanson, Andrew C. , Schroeder, Darrell R. , Flick, Randall P., Schroeder, Darrell , Warner, David O.

Mayo Clinic

Pediatric Anesthesia | March 15, 2018 | Volume: 28 | Issue: 6 | Pages: 513-519

10.1111/pan.13359 | PMID 29532559 Get It

SummaryBackgroundUtilization of general anesthesia in children has important policy, economic, and healthcare delivery implications, yet there is little information regarding the epidemiology of these procedures in the United States.AimsThe primary objective of this study was to describe in a geographically defined population the incidence of procedures requiring general anesthesia up to the child's third birthday, and the patient characteristics associated with receiving these procedures. A secondary objective was to determine the proportion of children in the population who meet the risk criteria promulgated by the Food and Drug Administration (FDA).MethodsA retrospective cohort of children born from 1994 to 2007 in Olmsted County, MN was established. Birth certificate information and receipt of general anesthesia before age 3 were collected. Proportional hazard regressions were performed to evaluate the association between characteristics of children and incidence of general anesthesia.ResultsAmong the 20 922 children in the cohort, 3120 (14.9%) underwent at least 1 general anesthesia before age 3. In multivariate regression, factors independently associated with receiving at least 1 procedure included prematurity, male sex, lower birth weight, cesarean delivery, a non‐Hispanic mother, and a White mother, controlling for multiple gestation, number of children previously born, age, education, and marital status of the mother. Seven hundred and twenty‐three children (3.5%) had at least 1 subsequent procedure. Estimated gestational age <32 weeks and low birth weight were independently associated with receiving repeated anesthesia. Eight hundred and twenty children (3.9%) had a single prolonged exposure above 3 hours, multiple exposures prior to age 3, or both.ConclusionApproximately 1 in 7 children were exposed to at least 1 episode of general anesthesia before age 3, and approximately 1 in 4 children who received general anesthesia fall within the high‐risk category as defined by the recent FDA warning. The apparent disparities in surgical utilization related to race and ethnicity in this study population deserve further exploration.
Thrombus Extension into the Common Femoral Vein after Endovenous Ablation of the Greater Saphenous Vein for the Treatment of Venous Insufficiency
Berland, Todd, Hakaim, Albert G., Oldenburg, W. Andrew, Paz‐Fumagalli, Ricardo , Turan, Naciye , Falkensammer, Juergen

Mayo Clinic

Journal for Vascular Ultrasound | March 14, 2018 | Volume: 30 | Issue: 3 | Pages: 129-131

10.1177/154431670603000303 Get It

Increasingly, endovenous ablation of the greater saphenous vein (GSV) is used for the treatment of symptomatic varicose veins. The propagation of thrombus can result in a “tail of thrombus” within the common femoral vein (CFV). In two cases, patients were treated with low molecular weight heparin and re-imaged within 1 week. In both cases, complete resolution of the thrombus was confirmed, and anticoagulation was discontinued. Thrombus extension into the CFV after endovenous ablation may be safely treated with short-term anticoagulation and followed by duplex ultrasound. If unresolved, standard deep vein thrombosis anticoagulation is indicated.
A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia
Chen, Xu , Gustafsson, Stefan , Whitington, Thomas, Borné, Yan , Lorentzen, Erik , Sun, Jitong , Almgren, Peter , Su, Jun , Lu, Yi , Zhan, Yiqiang , Hägg, Sara , Svensson, Per , Smedby, Karin E. , Lindgren, Cecilia M. , Morris, Andrew P. , Melander, Olle , Karlsson, Thomas , Fairé, Ulf dé , Lind, Lars , Pedersen, Nancy L. , Magnusson, Patrik K. E. , Lu, Yi , Karlsson, Robert , Song, Jie , Slager, Susan L. , Ingelsson, Erik , Caidahl, Kenneth , Engström, Gunnar , Karlsson, Mikael C. I. , Frostegård, Johan

Mayo Clinic

Human Molecular Genetics | March 14, 2018 | Volume: 27 | Issue: 10 | Pages: 1809-1818

10.1093/hmg/ddy094 | PMID 29547969 Get It

Association of sporadic and familial Barrett's esophagus with breast cancer
Chan, Megan , Blum, Andrew E., Chandar, Apoorva K., Emmons, Agnieszka, Shindo, Yuri, Brock, Wendy , Wang, J S, Iyer, Prasad G. , Shaheen, Nicholas J. , Thota, Prashanthi N. , Guda, Kishore , Chak, Amitabh , Falk, Gary W. , Canto, Marcia Irene , Grady, William M. , Abrams, Julian A

Mayo Clinic

Diseases of the Esophagus | March 8, 2018 | Volume: 31 | Issue: 4 | Pages: No page available

10.1093/dote/doy007 | PMID 29528378 Get It

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II
Tumlin, James A., Murugan, Raghavan , Deane, Adam M. , Ostermann, Marlies , Busse, Laurence W. , Ham, Kealy R., Szerlip, Harold M. , Prowle, John R. , Bihorac, Azra , Finkel, Kevin W., Zarbock, Alexander , Lynch, S., Jensen, Jeff, Kroll, Stew, Chawla, Lakhmir S. , Tidmarsh, George F., Karvellas, Constantine , Frendl, György , English, Shane , Grimaldi, David , Hite, R. Duncan , Camporota, Luigi , Young, Paul J. , Bihari, Shailesh , Bersten, Andrew D. , Karvellas, Constantine , Kashani, Kianoush , Forni, Lui G. , Lynch, Shannan J., Bellomo, Rinaldo , Bihorac, Azra , Ostermann, Marlies , Deane, Adam M , Young, Paul J , Poissy, Julien

Mayo Clinic

Critical Care Medicine | March 6, 2018 | Volume: 46 | Issue: 6 | Pages: 949-957

10.1097/ccm.0000000000003092 | PMID 29509568 Get It

Objective: Acute kidney injury requiring renal replacement therapy in severe vasodilatory shock is associated with an unfavorable prognosis. Angiotensin II treatment may help these patients by potentially restoring renal function without decreasing intrarenal oxygenation. We analyzed the impact of angiotensin II on the outcomes of acute kidney injury requiring renal replacement therapy. Design: Post hoc analysis of the Angiotensin II for the Treatment of High-Output Shock 3 trial. Setting: ICUs. Patients: Patients with acute kidney injury treated with renal replacement therapy at initiation of angiotensin II or placebo ( n = 45 and n = 60, respectively). Interventions: IV angiotensin II or placebo. Measurements and Main Results: Primary end point: survival through day 28; secondary outcomes included renal recovery through day 7 and increase in mean arterial pressure from baseline of ≥ 10 mm Hg or increase to ≥ 75 mm Hg at hour 3. Survival rates through day 28 were 53% (95% CI, 38%–67%) and 30% (95% CI, 19%–41%) in patients treated with angiotensin II and placebo ( p = 0.012), respectively. By day 7, 38% (95% CI, 25%–54%) of angiotensin II patients discontinued RRT versus 15% (95% CI, 8%–27%) placebo ( p = 0.007). Mean arterial pressure response was achieved in 53% (95% CI, 38%–68%) and 22% (95% CI, 12%–34%) of patients treated with angiotensin II and placebo ( p = 0.001), respectively. Conclusions: In patients with acute kidney injury requiring renal replacement therapy at study drug initiation, 28-day survival and mean arterial pressure response were higher, and rate of renal replacement therapy liberation was greater in the angiotensin II group versus the placebo group. These findings suggest that patients with vasodilatory shock and acute kidney injury requiring renal replacement therapy may preferentially benefit from angiotensin II.
A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study)
Starling, Amaal J. , Tepper, Stewart J. , Marmura, Michael J. , Shamim, Ejaz A. , Hindiyeh, Nada , Charles, Andrew , Goadsby, Peter J. , Silberstein, Stephen D., Gelfand, Amy A. , Chiacchierini, Richard P., Goadsby, Peter J , Marmura, Michael J , Robbins, Matthew S. , Lipton, Richard B. , Dodick, David W. , Charles, Andrew , Gelfand, Amy A

Mayo Clinic

Cephalalgia | March 5, 2018 | Volume: 38 | Issue: 6 | Pages: 1038-1048

10.1177/0333102418762525 | PMID 29504483 Get It

Objective To evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine. Background sTMS was originally developed for the acute treatment of migraine with aura. Open label experience has suggested a preventive benefit. The objective of this trial was to evaluate the efficacy and tolerability of sTMS for migraine prevention. Methods The eNeura SpringTMS Post-Market Observational U.S. Study of Migraine (ESPOUSE) Study was a multicenter, prospective, open label, observational study. From December 2014 to March 2016, patients with migraine (n = 263) were consented to complete a 1-month baseline headache diary followed by 3 months of treatment. The treatment protocol consisted of preventive (four pulses twice daily) and acute (three pulses repeated up to three times for each attack) treatment. Patients reported daily headache status, medication use, and device use with a monthly headache diary. The primary endpoint, mean reduction of headache days compared to baseline, was measured over the 28-day period during weeks 9 to 12. The primary endpoint was compared to a statistically-derived placebo estimate (performance goal). Secondary endpoints included: 50% responder rate, acute headache medication consumption, HIT-6, and mean reduction in total headache days from baseline of any intensity. Results Of a total of 263 consented subjects, 229 completed a baseline diary, and 220 were found to be eligible based on the number of headache days. The device was assigned to 217 subjects (Safety Data Set) and 132 were included in the intention to treat Full Analysis Set. For the primary endpoint, there was a −2.75 ± 0.40 mean reduction of headache days from baseline (9.06 days) compared to the performance goal (−0.63 days) ( p < 0.0001). The 50% responder rate of 46% (95% CI 37%, 56%) was also significantly higher ( p < 0.0001) than the performance goal (20%). There was a reduction of −2.93 (5.24) days of acute medication use, headache impact measured by HIT-6, −3.1 (6.4) ( p < 0.0001), and total headache days of any intensity −3.16 days (5.21) compared to the performance goal (−0.63 days) ( p < 0.0001). The most common adverse events were lightheadedness (3.7%), tingling (3.2%), and tinnitus (3.2%). There were no serious adverse events. Conclusions This open label study suggests that sTMS may be an effective, well-tolerated treatment option for migraine prevention. Trial registration number NCT02357381
Pulmonary embolism attenuation is a potential imaging biomarker for pulmonary artery hemodynamic improvement after catheter-directed thrombolysis
Takahashi, Edwin A. , Reisenauer, Christopher J., Stockland, Andrew H., Bjarnason, Haraldur , Neisen, Melissa , Neidert, Newton B. , Harmsen, William S. , Day, Courtney N. , Misra, Sanjay , Neisen, Melissa J, Misra, Sanjay , Takahashi, Edwin A , Bjarnason, Haraldur

Mayo Clinic

Vascular Medicine | March 2, 2018 | Volume: 23 | Issue: 2 | Pages: 134-138

10.1177/1358863x18756504 | PMID 29498612 Get It

This study examined the potential correlation between pulmonary embolism (PE) attenuation on computed tomography pulmonary angiography (CTPA) and pulmonary artery hemodynamic response to catheter-directed thrombolysis (CDT) in 10 patients with submassive PE. Treatment parameters, PE attenuation, clot burden, computed tomography signs of right ventricle dysfunction and right ventricular systolic pressure at echocardiography were retrospectively analyzed to determine correlation with pulmonary artery pressure improvement using Spearman correlation. A single reader, blinded to the treatment results, measured PE attenuation of all patients. There was a significant positive correlation between PE attenuation and absolute pulmonary artery pressure improvement with a Spearman correlation of 0.741, p=0.014. When attenuation was greater than or equal to the median (44.5 HU, n=5), CDT was associated with significantly better pulmonary artery pressure improvement ( p=0.037). Clot attenuation at CTPA may be a potential imaging biomarker for predicting pulmonary artery pressure improvement after CDT.
The use of cytapheresis in the treatment of infectious diseases
Norgan, Andrew P. , Pritt, Bobbi S. , Winters, Jeffrey L , Pritt, Bobbi S , Juskewitch, Justin E. , Winters, Jeffrey L. , Norgan, Andrew P

Mayo Clinic

Journal of Clinical Apheresis | February 28, 2018 | Volume: 33 | Issue: 4 | Pages: 529-537

10.1002/jca.21620 | PMID 29488237 Get It

Cytapheresis (removal of cellular blood components) has been employed for treatment of infectious diseases since the 1960s. Techniques have included thrombocytapheresis (buffy coat apheresis) for loiasis, erythrocytapheresis for malaria and babesiosis, and leukocytapheresis for pertussis‐associated lymphocytosis. Published data on these applications is largely limited to case level data and small observational studies; as such, recommendations for or against the use of cytapheresis in the treatment of infections have been extrapolated from these limited (and at times flawed) data sets. Consequently, utilization of cytapheresis in many instances is not uniform between institutions, and typically occurs at the discretion of treating medical teams. This review revisits the existing literature on the use of cytapheresis in the treatment of four infections (loasis, malaria, babesiosis, and pertussis) and examines the rationale underlying current treatment recommendations concerning its use.
TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficien
Ryan, Charles J. , Abida, Wassim , Dumbadze, Igor, Given, Robert , Petrylak, Daniel P. , Redfern, Charles H., Scher, Howard I. , Watkins, Simon P. , Simmons, Andrew D. , Passler, Luke, Golsorkhi, Tony, Chowdhury, Simon, Watkins, Simon P , Bryce, Alan H. , Balar, Arjun Vasant , Morris, David S. , Passler, Luke

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 6_suppl | Pages: TPS389-TPS389

10.1200/jco.2018.36.6_suppl.tps389 Get It

TPS389 Background: Recent data have shown that up to 25% of patients with advanced prostate cancer, including mCRPC, have a deleterious germline or somatic mutation in BRCA1, BRCA2, ATM, or another homologous recombination DNA repair gene. Such mutations can be used as a molecular marker to select patients for targeted treatment with poly(ADP-ribose) polymerase inhibitors (PARPis), which are lethal to cells with HRD. Treatment with PARPis has shown preliminary evidence of antitumor activity in patients with mCRPC and a mutation in a homologous recombination DNA repair gene (Mateo et al. N Engl J Med. 2015;373:1697-708). These data provide a compelling rationale for evaluating rucaparib, a potent inhibitor of PARP1, PARP2, and PARP3, in patients with mCRPC associated with HRD. Methods: TRITON3 (NCT02975934) is a randomized, phase 3 study evaluating rucaparib 600 mg BID vs physician’s choice of abiraterone, enzalutamide, or docetaxel in patients with mCRPC and a deleterious germline or somatic BRCA1, BRCA2, or ATM mutation (identified by prior local testing or central testing during screening). Patients must have progressed on androgen receptor signaling–directed therapy in the mCRPC setting; prior PARPi treatment or chemotherapy for mCRPC are exclusion criteria. Patients will be randomly assigned in a 2:1 ratio to either rucaparib or physician’s choice, with the possibility for cross over from the comparator treatment to rucaparib upon radiographic progression confirmed by independent radiology review. The primary endpoint is radiographic progression-free survival (modified RECIST v1.1/PCWG3 criteria) assessed by independent radiology review. Secondary endpoints include objective response rate, duration of response, patient-reported outcomes, overall survival, and safety. Pretreatment blood samples collected from all patients will enable development of a noninvasive plasma-based companion diagnostic to select patients who may benefit from rucaparib treatment. Patients (≈400) will be enrolled at > 100 sites worldwide. Clinical trial information: NCT02975934.